Viking Therapeutics Q3 2026: trials on track, spending up 44% and nearly $1 billion in cash
Did the story change? Mixed
Not its direction. Viking's Phase 3 injection trials remain on track to finish in 2027, and the tablet's Phase 3 programme began in October. What changed is the cost: research and development expense rose to $166.8 million from $115.8 million in Q2, and the net loss to $183.2 million. The September share and note sales lifted cash and short-term investments to $960 million, which Viking says gives it the runway to complete its Phase 3 obesity trials.
Snapshot at the Oct 28, 2026 close
- Market value
- $3.0B
- Cash and investments
- $502M
- Enterprise value
- $2.5B
- Cash use per quarter
- $105M
- Price/sales
- n/m
- P/E
- n/m
Our calculation from the company's filings (latest: 10-Q for the quarter to Jun 30, 2026, filed Jul 29, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Jun 30, 2026. Price $25.36 (official close, Nasdaq historical quotes). n/m = not meaningful (e.g. negative earnings).
Viking Therapeutics’ third-quarter release shows expenses rising while its trial timelines held. Research and development expense, which includes stock-based pay, rose 44% from the second quarter and the net loss widened to $183.2 million. The September share and convertible-note sales left Viking with $960 million of cash and short-term investments at quarter-end. Viking has no product sales. It identifies VK2735, an obesity drug, as its lead program. It is in Phase 3, large trials intended to support an application for regulatory approval, as a weekly injection and, since October, as a daily tablet.
Did the story change?
Neither quarterly release gives a numerical spending or loss forecast, so the table compares reported results and management’s cash and trial outlooks in July and October.
| Driver | Q2 → Q3 2026 | Management: July → October | Signal |
|---|---|---|---|
| Expenses and net loss | R&D $115.8M → $166.8M; net loss $128.0M → $183.2M | No financial guidance; the increase from a year earlier was attributed to clinical studies, manufacturing, stock pay, salaries and consultants | Worse |
| Cash and runway | Cash and short-term investments $502M → $960M, after about $550M of net offering proceeds | Cash to last “through at least September 30, 2027” (before the raise) → runway to reach milestones “including completion of the company’s ongoing Phase 3 obesity trials” | Better |
| VANQUISH Phase 3 (injection) | Fully enrolled; “continued to advance on track” | “Proceeding according to plan” → completion expected in 2027; extension studies to start in Q1 2027 | Unchanged |
| Tablet and maintenance studies | SUNRISE Phase 3 started Oct 14; maintenance study Part 2 started | Tablet Phase 3 expected in Q4 2026 (February had said Q3) → started Oct 14; Part 2 results expected in 2027 | Unchanged |
| VK3019 | Phase 1 single-dose study “nearing completion” | Phase 1 “underway” → single-dose study to finish this quarter, multiple-dose study in Q1 2027 | Unchanged |
Sources: the company’s Q2 and Q3 releases and Q2 10-Q. The 44% and 43% increases are our calculations.
What got better
Cash
In September Viking sold 9.04 million shares at $35.00 and $258.75 million of 2% convertible notes due 2032, raising about $575 million gross. Viking says the money provides the runway to complete its Phase 3 obesity trials and supports its growing commercial operations as it prepares for a possible launch.
Trial timing
Viking says VANQUISH, its two trials of the weekly injection with about 5,500 patients in total, remains on track for completion in 2027. Viking expects extension studies to start in Q1 2027 and report results in 2028. They allow up to 52 additional weeks of treatment; VANQUISH-1’s extension will also test every-other-week and monthly dosing.
Tablet and maintenance studies
Viking announced SUNRISE’s start on October 14. Each of the two tablet trials targets 560 adults receiving treatment for 68 weeks. Part 2 of the maintenance study, which tests tablets and less frequent injections after weight loss, also began; results are expected in 2027.
What needs watching
Research and administrative expense
R&D expense of $166.8 million, including stock-based pay, was the highest of the past four quarters (Q4 2025: $153.5 million; Q1 2026: $150.2 million; Q2: $115.8 million). General and administrative expense rose to $20.3 million from $8.6 million a year earlier.
Cash use
The release omits a cash flow statement; operating cash use awaits the 10-Q. Reported accounts payable and other accrued liabilities rose from $109.5 million at June 30 to $133.9 million at September 30. These balances are not a measure of quarterly cash use.
Dilution
Viking’s reported share count rose from 116.7 million at June 30 to 127.5 million at September 30, mainly following the $35 public offering and sales through its at-the-market programme. At the initial conversion rate, the notes represent about 5.1 million shares at approximately $50.75 each. Viking can settle conversions in cash, shares or both; unconverted notes mature in October 2032. The September 23 prospectus said Viking could sell another $449.8 million of shares through its at-the-market programme, which sells new shares gradually into the market, after the lock-up that applies to Viking expired or was waived.
Ligand dispute
Viking’s Q2 filing says Ligand purported to terminate the licence covering VK2809 and VK0214 in April, then sued in May to enforce post-termination obligations and seek damages. Viking contests the termination and filed a cross-complaint. An adverse outcome could cost Viking rights to both drugs. The Q3 release gives no update.
Does this change the long-term story?
Our read: the development plan remains broadly intact. The oral Phase 3 trials started within the Q4 window Viking gave in July, after its February outlook had called for a Q3 start. The financing followed Viking’s September 22 report that less frequent injections helped participants maintain weight loss better than placebo in an early study. Whether VK2735 succeeds still depends on larger trials establishing its safety and effectiveness. The open questions are the same as before: what VANQUISH ultimately shows, and how Viking pays for a launch, alone or with a partner.
For the full record of filings, dilution and cash, see Viking Therapeutics: The Long View.
What to watch next
- Next filing
- The Q3 10-Q, with the full cash flow statement and any update on Ligand's lawsuit over the VK2809 licence.
- Nov 14–15, 2026
- Two VK2735 posters at ObesityWeek: VANQUISH-2 baseline characteristics and cardiometabolic results from the Phase 2 VENTURE study.
- Q4 2026
- Viking expects to complete the single-dose Phase 1 study of VK3019, its experimental obesity treatment that activates receptors for amylin and calcitonin, hormones involved in appetite and metabolism.
- Q1 2027
- Start of the VANQUISH extension studies, including every-other-week and monthly dosing, and of a 4-week multiple-dose VK3019 study.
- 2027
- Viking expects the 78-week VANQUISH Phase 3 trials to be completed, and results from Part 2 of its maintenance dosing study.
Quick questions
How much cash does Viking have after Q3?
$960 million of cash, cash equivalents and short-term investments at Sep 30, 2026, including about $550 million of net proceeds from the September share and convertible-note offerings.
Why did Viking's loss widen in Q3?
Research and development expense rose to $166.8 million from $115.8 million in Q2. Viking attributed the increase from a year earlier to clinical studies, drug manufacturing, stock-based pay, salaries and consultants.
When are the VANQUISH Phase 3 results due?
Viking expects the two 78-week VANQUISH trials of injectable VK2735 to be completed in 2027; it has not given a date for the results.
About Viking Therapeutics: Website (external site)Investor relations (external site)SEC filings (external site)
+ 5 more
Accessed Oct 28, 2026: Viking Therapeutics: Q1 2026 results (SEC filing) · Viking Therapeutics: Q4 2025 results (SEC filing) · Viking Therapeutics: Q2 2026 10-Q · Viking Therapeutics: share offering prospectus supplement (Sep 25, 2026) · Viking Therapeutics: SUNRISE oral Phase 3 initiation (Oct 14, 2026)
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.